Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Monaldi Archives for Chest Disease is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Monaldi Arch Chest Dis 2021 [Online ahead of print]

To cite this Article:
Ratti G, Maglione A, Biglietto E, et al. Long term dual antiplatelet therapy after myocardial infarction: retrospective analysis in an outpatient population. Monaldi Arch Chest Dis doi: 10.4081/monaldi.2021.1881
Long term dual antiplatelet therapy after myocardial infarction: retrospective analysis in an outpatient population

Gennaro Ratti¹, Antonio Maglione¹, Emilia Biglietto¹, Cinzia Monda¹, Ciro Elettrico¹, Federica Ratti², Cosimo Fulgione², Mario Mallardo¹, Paolo Tammaro¹

¹Cardiology/ICU Department; ²Cardiac Rehabilitation, S. Gennaro Hospital, Naples, Italy

Corresponding author: Gennaro Ratti, Cardiology/ICU Department, S. Gennaro Hospital, Naples, Italy. Tel. +39.081.2545268. E-mail: genratti@virgilio.it

Key words: Antiplatelet agents; dual antiplatelet therapy; high ischemic risk; percutaneous coronary intervention.

Ethics approval: This is a retrospective study based on clinical data collected in an outpatient clinic. The study was conducted in accordance with the Helsinki Declaration as revised in 2013. The manuscript does not contain any individual person’s data in any form.

Author contributions: All the authors made a substantive intellectual contribution. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Disclosure of conflict of interests: The authors have no conflicts of interest to declare and there is no financial interest to report.

Abstract

Long term treatment with ticagrelor 60 mg and low-dose aspirin are indicated after acute coronary syndrome (ACS). We retrospectively reviewed aggregate data of 187 patients (155 M and 38 F) (mean age 63.8±9 years) in follow up after ACS with at least one high risk condition (Multivessel disease, diabetes, GFR<60 mL/min, history of prior myocardial infarction, age >65 years) treated with ticagrelor 60 mg twice daily (after 90 mg twice daily for 12 months). The results were compared with findings (characteristics of the patients at baseline, outcomes, bleeding) of PEGASUS-TIMI 54 trial and Eu Label. The highrisk groups were represented as follows: multivessel disease 105 pts
(82%), diabetes 63 pts (33%), GFR< 60 mL/min 27 pts (14%), history of prior MI 33 pts (17%), >65 year aged 85 pts (45%). Treatment was withdrawn in 7 patients: 3 cases showed atrial fibrillation and were placed on oral anticoagulant drugs, one developed intracranial bleeding, in three patients a temporary withdrawal was due to surgery (1 colon polyposis and 2 cases of bladder papilloma). Chest pain without myocardial infarction occurred in 16 patients (revascularization was required in 9 patients). Dyspnea was present in 15 patients, but was not a cause for discontinuation of therapy. Long term treatment with ticagrelor 60 mg twice daily plus aspirin 100 mg/day showed a favourable benefit/risk profile after ACS. In this study all patients had been given ticagrelor 90 mg twice daily for 12 months and the 60 mg twice daily dosage was started immediately thereafter, unlike PEGASUS-TIMI 54 trial in which it was prescribed within a period ranging from 1 day to 1 year after discontinuation of the 90 mg dose. This makes our results more consistent with current clinical practice. However, a careful outpatient follow-up and constant counseling are mandatory to check out compliance to therapy and adverse side effects.

Introduction
Ticagrelor, orally administered P2Y₁₂ inhibitor is indicated in a long-term regimen at dose of 60 mg twice daily in co-administration with low-dose aspirin 75–150 mg/day for the secondary prevention of atherothrombotic events in high-risk patients with a history of myocardial infarction (MI) occurred at least 1 year. Evidence is based on the results of the PEGASUS-TIMI 54 trial that compared ticagrelor with placebo (in association with aspirin) in stable patients after MI occurred 1–3 years prior to enrolment with high risk of atherothrombotic events. Subsequently treatment with ticagrelor 60 mg twice daily, as recommended in the European (Eu) label, initiated up to 2 years from the myocardial infarction, or within 1 year after stopping previous treatment with 90 mg twice daily, confirmed a relative risk reduction in CV death, MI, or stroke. Long term dual antiplatelet therapy (DAPT) was well tolerated, but the risk of TIMI major bleeding (primary safety endpoint) was significantly increased in ticagrelor 60 mg twice daily versus placebo recipients; however, the risk appeared to decline after the first year of therapy. The increased use of ticagrelor was not associated with intracranial hemorrhage (ICH), whereas age and prior cardiovascular morbidities were related to the risk of ICH and a significant interaction was found.

Aim of study: To compare the results of PEGASUS-TIMI 54 trial and Eu Label studies with those of our clinical experience in a secondary prevention outpatient clinic.
Methods
We retrospectively reviewed data of 187 consecutive patients without exclusion criteria, scheduled from September 2017 to July 2020 (149 M and 38 F) (mean age 63.8±9 years with at least one high risk condition (Multivessel disease, Diabetes, GFR< 60 ml/min, history of prior MI, age >65 years) attending our outpatient clinic after ACS. All patients had been one year on DAPT with ticagrelor 90 mg twice daily and aspirin 100 mg/day. Thereafter, the patients had been shifted to a long term DAPT with ticagrelor 60 mg twice daily and aspirin 100 mg/day according to clinical indications (presence of at least one of the following high-risk conditions: multiple vessel disease, diabetes, GFR<60 ml/min, previous myocardial infarction, age> 65 years). According to hospital protocol, after discharge from hospital patients were seen at day 30 and after 3 months, then at six-month intervals. The intensity of bleeding was assessed according to the TIMI score. Any overt bleeding event that did not meet the criteria of major and minor was defined “minimal”. The results were compared with results of PEGASUS-TIMI 54 trial and Eu Label.

Statistical analysis
For the comparison between independent samples, the prevalence zeta test was used for the values expressed as a percentage and the Student's t-test for the values expressed as means. A p≤0.05 value was considered statistically significant.

Results
The median duration of follow-up after the start of treatment with the 60 mg dosage was 17.3 ± 9.4 months. The characteristics of patients are shown in Table 1. The high-risk conditions were represented as follows: 155 pts with multiple vessel disease (82%), 63 pts with diabetes (33%), 27 pts with chronic renal failure (GFR<60 ml/min) (14%), 33 pts with previous myocardial infarction (17%), 85 pts with age> 65 years (45%). Tables 2 and 3 compare the clinical events and bleeding of the groups, respectively. Chest pain with no evidence of ECG and troponin evidence of MI occurred in 16 patients (8.5%). After angiography, however revascularisation was required in nine of 16 patients. The characteristics of bleedings are shown in table 4 and 5. DAPT was stopped in 7 patients: onset of atrial fibrillation and prescription of oral anticoagulant (3 cases), intracranial haemorrhage which left no clinical reliquates (1 case), and in 3 cases a temporary withdrawal was necessary for surgery procedure (1 case of colon polyposis and 2 of bladder papilloma). Adverse events are reported in table 6. Dyspnea (described as sudden and unexpected starvation of air or unsatisfactory inspiration) was reported in 15 patients (8%), but it was judged to be non-limiting and did not cause treatment discontinuation. All patients received pump inhibitors for gastric protection.
Discussion

Multivessel patients are less represented in our study as compared with PEGASUS TIMI 54 and Eu Label. This is only partially explained by the higher percentage of males in our study. Hypercholesterolemic patients are less represented in our study probably because undeclared statin treatment at admission in intensive coronary unit (ICU).

Previous clinical practice observations had confirmed safety of the long term DAPT with ticagrelor\(^5\). The most frequent adverse events are essentially dyspnea and minor bleeding. No increase in intracranial bleeding was observed\(^6\), although this risk is increased in elderly patients\(^4\). Our data confirm these findings and only 1 case of intracranial bleeding occurred at days 30 after switching to dose of 60 mg twice daily. No clinically significant outcome was observed.

Compared with PEGASUS-TIMI 54 trial, in our study dyspnea was less reported, probably because our patients in 1 year of 90 mg ticagrelor treatment had shown to be resistant to this side-effect. Non-serious side effects (especially minimal bleeding and non-limiting dyspnea) may cause DAPT discontinuations that are often unnecessary\(^7\). These discontinuations can be prevented by adequate counseling to increase adherence to medication, compliance and improve clinical efficacy.\(^4\),\(^8\)-\(^9\) In particular, dyspnea should be considered only if it is clinically limiting\(^10\). All adverse events judged to be "not serious" in trials may have an effect on quality of life\(^11\) and therefore may lead to treatment discontinuation. The need to educate the patient in order to improve adherence should therefore be emphasized.\(^12\)

Study limitations

The study compare the results of PEGASUS-TIMI 54 trial and Eu Label with those of our clinical experience in a secondary prevention outpatient clinic, but the study design and the sample size widely differ between the two trials and the our investigation. In this study all patients had been given ticagrelor 90 mg twice daily for 12 months and the 60 mg twice daily dosage was started immediately thereafter, unlike PEGASUS-TIMI 54 trial in which it was prescribed within a period ranging from 1 day to 1 year after discontinuation of the 90 mg dose.

In our study (according to clinical indications) all patients had been on ticagrelor 90 mg BID for 12 months and the 60 mg BID regimen was started immediately at the end of 12th month, unlike PEGASUS-TIMI 54 trial in which P2Y12 therapy prior to randomization was clopidogrel in 94% of cases, prasugrel in 5%, ticagrelor in <1%, and ticlopidine in <1%.\(^13\)
Conclusions

(1) Long term DAPT with ticagrelor 60 mg BID with low-dose aspirin (100 mg/day) in secondary prevention after ACS, as recommended in the Eu label, appears to be characterized by a favorable risk/benefit ratio.

(2) Although the comparisons were made with the PEGASUS-TIMI 54 trial and Eu Label, in this study all patients had been on ticagrelor 90 mg BID for 12 months and the 60 mg BID regimen was started immediately at the end of 12th month, unlike PEGASUS-TIMI 54 trial in which P2Y12 therapy prior to Ticagrelor 60 mg BID was mostly clopidogrel 75 mg. This is a limitation of study but it makes our results more similar to what is observed in current clinical practice.

(3) However, the authors underline the importance of careful outpatient follow-up and constant counselling in order to check out compliance and possible adverse effect of DAPT treatment.

References

1. Bonaca MP, Bhatt DL, Cohen M, et al. For the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800.
2. Dellborg M, Bonaca MP, Storey RF, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European Label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother 2019;5:200-6.
3. Al-Salama ZT, Keating GM, Keam SJ. Ticagrelor: A review in long term secondary prevention of cardiovascular events. Drugs 2017;77:2025–36.
4. Graipe A, Söderström L, Mooe T. Increased use of ticagrelor after myocardial infarction not associated with Intracranial hemorrhage. Results from a Nationwide Swedish Registry. Stroke 2018;49:2877-82.
5. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47.
6. Cesaro A, Taglialatela V, Gragnano F, et al. Low-dose ticagrelor in patients with high ischemic risk and previous myocardial infarction: a multicenter prospective real-world observational study. J Cardiovasc Pharmacol 2020;76:173–80.
7. Bonaca MP, Bhatt DL, Ophuis TO, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events. A secondary analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol 2016;1:425-32.
8. Keenan J. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol 2017;24:s29–35.
9. Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J 2011;32:264–8.
10. Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care 2015;4:555–60.
11. Amin AP, Bachuwar A, ReidKJ, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 2013; 61:2130–8.

12. Ratti G, Lizzadro A, Biglietto E, et al. Long term dual antiplatelet therapy for secondary prevention: management model and our experience. Eur Heart J 2020;22:G205-6.

13. Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016;37:1133–42.
Tab. 1 - Characteristics of the patients at baseline.

| Characteristic                      | S. G. BOSCO 187 patients | PEGASUS 7045 patients | p     | Eu Label 5388 patients | p     |
|-------------------------------------|---------------------------|-----------------------|-------|-------------------------|-------|
| **Age (yrs)**                       | 63.8±9                    | 65.2 ± 8.4            | 0.049 | 65.1 ± 8.5              | 0.049 |
| **Female sex**                      | 38 (20,3)                 | 1661 (23,9)           | 0.248 | 1267 (23.9)             | 0.248 |
| **Wheigt (Kg)**                     | 82.4 ± 9.7                | 82.0 ± 17             | 0.159 | 81.9 ± 17.1             | 0.481 |
| **Hypertension**                    | 153 (81.8)                | 5461 (77.5)           | 0.159 | 4183 (77.65)            | 0.168 |
| **Hypercholesterolemia**            | 55 (29.4)                 | 5380 (76.4)           | <0.001| 4122 (76.52)            | <0.001|
| **Current smoker**                  | 27 (14.4)                 | 1206 (17.1)           | 0.326 | 939 (17.43)             | 0.279 |
| **Diabetes mellitus**               | 63 (33.6)                 | 2308 (32.8)           | 0.815 | 1774 (32.93)            | 0.383 |
| **GFR<60 ml/min**                   | 27 (14.4)                 | 1547/6955 (22.2)      | 0.01  | 1178 (22.16)            | 0.011 |
| **History of PCI**                  | 178 (95.1)                | 5879/7044 (83,5)      | <0.0001| 4584 (85.09)            | <0.0001|
| **Multivessel coronary artery disease** | 155 (82.8)             | 4190/7042 (59.5)      | <0.0001| 3313 (61.5)             | <0.0001|
| **Prior myocardial infarction**     | 33 (17.6)                 | 1168 (16.6)           | 0.713 | 884 (16.41)             | 0.657 |
| **Peripheral-artery disease**       | 17 (9.0)                  | 368 (5.2)             | <0.0001| 301 (5.59)              | <0.0001|
| **Years since myocardial infarction** | 1                      | 1.7 (1.2-3.2)        | ------| 1.5 (1-2)              | ------|
| **STEMI**                           | 50 (26.7)                 | 3757/7035 (53.4)      | <0.001| 2872(53.35)             | <0.001|
| **NSTEMI**                          | 138 (73.7)                | 2842/7035 (40.4)      | <0.0001| 2209(41.04)             | <0.0001|
| **Treatment with Aspirin**          | 187 (100)                 | 7036 (99.9)           | 0.665 | 5681(99.87)             | 0.540 |
| **Treatment with Statin**           | 184 (98.3)                | 6495 (92.2)           | 0.0018| 4999 (92.78)            | 0.0032|
| **Treatment with Beta-blocker**     | 151 (80.7)                | 5796 (82.3)           | 0.566 | 4462 (82.81)            | 0.446 |
| **Treatment with ACE inhibitor or ARB** | 155 (82.8)            | 5631 (79.9)           | 0.332 | 4310 (79.99)            | 0.332 |

PCI = percutaneous coronary intervention.
GFR = glomerular filtration rate.
STEMI = ST-segment elevation myocardial infarction.
NSTEMI = non–ST-segment elevation myocardial infarction.
ACE = angiotensin-converting enzyme.
ARBS = angiotensin-receptor blockers.
Tab. 2 – Outcomes

|                          | S. G. BOSCO | PEGASUS | p       | Eu Label | p       |
|--------------------------|-------------|---------|---------|----------|---------|
|                          | 187 patients| 7045 patients| <0.0001| 5388 patients| <0.0001|
| Cardiovascular death     | 1 (0.05)   | 174 (2.86) | <0.0001| 119 (2.58) | <0.0001|
| Death from coronary heart disease | 0         | 106 (1.72) | <0.0001| 75 (1.59) | <0.0001|
| Myocardial infarction    | 7 (3.7)    | 285 (4.5)  | 0.028   | 230 (4.2) | 0.165   |
| Stroke – any             | 1 (0.05)   | 100 (1.61) | <0.0001| 71 (1.5)  | <0.0001|
| Death from any cause     | 1 (0.05)   | 289 (4.69) | <0.0001| 206 (3.8) | <0.0001|

Tab. 3 – Bleeding

|                          | S. G. BOSCO | PEGASUS | p       | Eu Label | p       |
|--------------------------|-------------|---------|---------|----------|---------|
|                          | 187 patients| 7045 patients| <0.0001| 5388 patients| <0.0001|
| TIMI Major               | 0           | 115 (2.30) | <0.0001| 94 (1.7)  | <0.0001|
| TIMI Minor               | 7 (3.7)     | 55 (1.18)  | <0.0001| 49 (0.9)  | <0.0001|
| Intracranial hemorrhage  | 1 (0.53)    | 28 (0.61)  | 0.647   | 23 (0.42) | 0.453   |
| Fatal bleeding           | 0           | 11 (0.25)  | 0.608   | 27 (0.5)  | 0.0017  |

Tab. 4 – Minor bleeding

|                          | S. G. BOSCO | p       |         |
|--------------------------|-------------|---------|---------|
|                          | 187 patients|         |         |
| Total Minor bleeding     | 7 (3.7)     |         |         |
| Treatment-limiting bleeding* | 4 (2.1)  |         |         |
| No treatment-limiting bleeding | 3 (1.6) |         |         |
| Hematuria                | 2 (1.0)     |         |         |
| Rectal bleeding          | 5 (2.6)     |         |         |

*3 patients temporarily for non-cardiac surgery (1 case of colon polyposis and 2 cases of bladder papilloma)
Tab. 5 – Minimal bleeding

|                                | S. G. BOSCO n (%) |
|--------------------------------|-------------------|
| **Total**                      | 31 (16.5)         |
| **Subcutaneous/dermal**        | 19 (10.1)         |
| **Epistaxis**                  | 1 (0.53)          |
| **Hematuria**                  | 4 (2.1)           |
| **Rectal**                     | 5 (2.6)           |
| **Gingival**                   | 1 (0.53)          |
| **Conjunctival bleeding**      | 1 (0.53)          |

^ patients with minor bleeding (nasal, gingival, rectal, and urinary) did not require treatment interruption.

Tab. 6 – Adverse events

|                                | S. G. BOSCO n (%) | PEGASUS n (%) | p     |
|--------------------------------|-------------------|---------------|-------|
| **Dyspnea**                    | 15 (8.0)          | 987 (15.84)   | < 0.0001 |
| **Limiting dyspnea**           | 0                 | 297 (4.55)    | < 0.0001 |
| **Severe dyspnea**             | 0                 | 23 (0.45)     | 0.0029  |
| **Bradyarrhythmia**            | 0                 | 121 (2.32)    | < 0.0001 |
| **Gout**                       | 0                 | 101 (1.97)    | < 0.001  |
| **Renal event**                | 0                 | 173 (3.43)    | < 0.001  |